175647-03-7

Basic information

• Product Name: 2,3-DIHYDRO-1H-INDOLE-4-CARBOXYLIC ACID
• Synonyms: 2,3-DIHYDRO-1H-INDOLE-4-CARBOXYLIC ACID;1H-Indole-4-carboxylicacid,2,3-dihydro-
• CAS NO: 175647-03-7
• Molecular Formula: C9H9NO2
• Molecular Weight: 163.17
• Mol File: 175647-03-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,3-DIHYDRO-1H-INDOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1H-INDOLE-4-CARBOXYLIC ACID(175647-03-7)
• EPA Substance Registry System: 2,3-DIHYDRO-1H-INDOLE-4-CARBOXYLIC ACID(175647-03-7)

Safety Data

• Hazardous Substances Data: 175647-03-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydro-1H-indole-4-carboxylic acid is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activities, including anticancer properties. It plays a crucial role in the development of new drugs targeting various types of cancer.
Used in Agrochemical Industry:
In the agrochemical industry, 2,3-dihydro-1H-indole-4-carboxylic acid is utilized as a building block in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Dyes and Pigments Production:
2,3-Dihydro-1H-indole-4-carboxylic acid is employed as a key component in the production of dyes and pigments, owing to its ability to impart color and stability to various materials.
Used in Medicinal Chemistry Research:
Due to its diverse biological activities, such as antimicrobial properties, 2,3-dihydro-1H-indole-4-carboxylic acid is a valuable compound in medicinal chemistry research. It serves as a promising candidate for the development of new therapeutic agents and the study of its interactions with biological systems.

Upstream product

• 155135-61-8 methyl indoline-4-carboxylate 
• 39830-66-5 methyl 1H-indole-4-carboxylate 
• 2124-55-2 1H-indole-4-carboxylic acid 

Downstream Products

• 208774-11-2 2,3-dihydro-indole-1,4-dicarboxylic acid 1-tert-butyl ester 

Relevant articles and documents

Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies

Here, we report the synthesis, structure-activity relationship studies, enzyme inhibition, antiviral activity, and X-ray crystallographic studies of 5-chloropyridinyl indole carboxylate derivatives as a potent class of SARS-CoV-2 chymotrypsin-like protease inhibitors. Compound 1 exhibited a SARS-CoV-2 3CLpro inhibitory IC50 value of 250 nM and an antiviral EC50 value of 2.8 μM in VeroE6 cells. Remdesivir, an RNA-dependent RNA polymerase inhibitor, showed an antiviral EC50 value of 1.2 μM in the same assay. Compound 1 showed comparable antiviral activity with remdesivir in immunocytochemistry assays. Compound 7d with an N-allyl derivative showed the most potent enzyme inhibitory IC50 value of 73 nM. To obtain molecular insight into the binding properties of these molecules, X-ray crystal structures of compounds 2, 7b, and 9d-bound to SARS-CoV 3CLpro were determined, and their binding properties were compared.

HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES

This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical compositions containing s

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.